Proteome Regulatory News (PRM)

17 Aug 2007 18:15

Proteome Sciences Plc ("Proteome Sciences" or "the Company")

17 August 2007

AIM Rule 26 Compliant Website and Change of Adviser Name

Proteome Sciences plc ("Proteome Sciences") today announces that the information required by Rule 26 of the AIM Rules for Companies (February 2007) is available within the "Rule 26" section of the Company's website at www.proteomics.com

The Company today also announces that with effect from 9 August 2007, the name of the Company's nominated adviser and broker has changed to Landsbanki Securities (UK) Limited.

Ends Notes to editors:

Proteome Sciences plc applies high sensitivity proteomics to identify and characterise differential protein expression in diseases for diagnostic, prognostic and therapeutic applications. It has discovered blood biomarkers principally for stroke, vCJD, BSE, brain damage, solid organ transplant rejection and Alzheimer's disease. The main focus of its research currently addresses neurological, neurodegenerative, oncology and cardiovascular conditions.

In addition to its own proprietary biomarkers, Proteome Sciences has developedProteoSHOP‚® (Proteome Sciences High Output Proteomics), a toolbox that offershigh sensitivity and high throughput gel and gel-free proprietary technologiesfor the identification and validation of potential biomarkers and drug targets,including specialisation in membrane proteins and protein phosphorylation. The Company has developed a range of specialist reagents to improve theperformance and quantitation of protein separation and characterisation withmass spectrometry, bioinformatics, statistics and pattern recognition. Theseinclude Sensitizer‚®, PST‚®, qPST¢â€ž¢ and TMT‚®. Proteome Sciences has patentallowances in the major global jurisdictions for isobaric tandem mass tags (TMT‚®) for the manufacture and use of any type of isobaric mass tags.

Commercialisation is actively pursued across the portfolio of the Company's programmes and technologies with licensing deals signed in biomarkers for Stroke and TSEs and for ProteoSHOP‚®.

Proteome Sciences has its headquarters in Cobham, Surrey in the UK and has laboratories at Kings College Hospital, London and Frankfurt Innovations Zentrum (FIZ), Frankfurt. It employs 32 full time scientists in addition to its corporate and business development staff, and has collaborative research agreements with leading academic institutes. The Company is listed on the Alternative Investment Market.

For further information please visit www.proteomics.com.

Proteome Sciences plc

James Malthouse, Finance Director

Email: james.malthouse@proteomics.com

Christopher Pearce, Chief Executive Officer

Email: christopher.pearce@proteomics.com

Tel: +44 (0)1932 865065 Public Relations IKON Associates Coast CommunicationsAdrian Shaw Matt BaldwinTel: +44 (0)1483 535102 Tel: +44 (0)1233 503200Mobile: +44 (0)797 9900733 Mobile: +44 (0)7930 439739Email: adrian@ikonassociates.com Email: matt@coastcommunications.com Nominated Adviser

Landsbanki Securities (UK) Limited

Thilo Hoffman

Tel: +44 (0)20 7426 9000